Core Viewpoint - A federal securities class action has been filed against Charming Medical Ltd. for alleged violations of the Securities Exchange Act of 1934, following a significant and artificial increase in its stock price during the class period from October 21, 2025, to November 12, 2025 [1][2]. Group 1: Allegations and Stock Performance - The lawsuit claims that Charming Medical's stock price surged from $4.00 to a high of $29.36 without any fundamental news, indicating potential market manipulation [2]. - Plaintiffs allege that the price increase was driven by a fraudulent social-media-based stock promotion scheme, where impersonators posed as financial advisors to promote the stock with unsupported claims [3]. - Trading in Charming Medical securities was suspended in November 2025, revealing the artificial nature of the stock price increase and leading to investor losses [4]. Group 2: Legal Proceedings and Investor Actions - The proposed class includes all individuals and entities who purchased Charming Medical securities during the class period and suffered damages, excluding defendants and their affiliates [4]. - Investors have until February 17, 2026, to seek appointments as lead plaintiff in the class action [1][4]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP, founded in 1888, specializes in securities litigation and has a long history of advocating for investors who have suffered financial harm due to misrepresented statements [6]. - The firm encourages affected investors to contact them for assistance in the ongoing investigation [6].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Ramaco Resources, Inc. for possible securities fraud, potentially leading to a class action lawsuit on behalf of investors [1]. Group 1: Investigation and Legal Actions - The Portnoy Law Firm is encouraging investors to contact them to discuss their legal rights and options for pursuing claims to recover losses [2]. - The investigation follows a report by Wolfpack Research, which alleged that Ramaco's Brook Mine project was a "hoax" and that the company manipulated data to misrepresent profitability [3]. Group 2: Stock Price Impact - Following the allegations from Wolfpack Research, Ramaco's stock price dropped by $3.81, or 9.5%, closing at $36.01 per share on October 23, 2025, resulting in financial harm to investors [3]. Group 3: Firm's Background - The Portnoy Law Firm has a history of representing investors in claims related to corporate wrongdoing, having recovered over $5.5 billion for aggrieved investors [4].

Core Viewpoint - A class action securities lawsuit has been filed against DeFi Technologies, alleging securities fraud that affected investors between May 12, 2025, and November 14, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that DeFi Technologies faced delays in executing its DeFi arbitrage strategy, which was a key revenue driver for the company [2] - It is alleged that DeFi Technologies understated the competition from other digital asset treasury companies, impacting its ability to execute its DeFi arbitrage strategy [2] - The company is said to be unlikely to meet its previously issued revenue guidance for the fiscal year 2025 due to these issues [2] - Defendants allegedly downplayed the true scope and severity of the negative impacts on DeFi Technologies' business and financial results [2] - Public statements made by the defendants were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses in DeFi Technologies during the relevant time frame have until January 30, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Avantor, Inc. ("Avantor, Inc." or the "Company") (NYSE: AVTR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avantor, Inc. investors who were adversely affected by alleged securities fraud between March 5, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/avantor-inc-lawsuit-s ...

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was claimed to be less effective than represented [2]. - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings Corporation materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until February 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a track record of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Ardent Health, Inc., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2]. Company Overview - Ardent Health, Inc. is a healthcare provider operating in growing midsize urban communities across the United States [2]. - The company raised $192 million in its initial public offering on July 18, 2024, selling 12 million shares at $16 per share [2]. Recent Developments - On November 12, 2025, Ardent Health announced its third quarter 2025 earnings, which missed consensus estimates primarily due to pronounced payor denials and a $54 million adjustment related to adverse prior period claim developments from 2019 to 2022 [3]. - The CFO, Alfred Lumsdaine, indicated that a "change in accounting estimate" led to the earlier recognition of reserves, resulting in a revenue reduction of $43 million for the quarter [3].

Core Viewpoint - The F5 class action lawsuit alleges that F5, Inc. and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in light of a significant security incident that impacted its operations and stock price [1][4]. Group 1: Lawsuit Details - The lawsuit is titled Smith v. F5, Inc., No. 25-cv-02619 (W.D. Wash.) and aims to represent purchasers or acquirers of F5 securities [1]. - The lawsuit claims that F5 created a false impression of its financial health and minimized risks associated with seasonality and macroeconomic factors [4]. - On October 15, 2025, F5 disclosed a security breach involving a nation-state threat actor, leading to a nearly 14% drop in stock price over two trading days [5]. - Following the breach, F5 reported fourth quarter fiscal year 2025 results that fell significantly below market expectations, resulting in an additional nearly 11% decline in stock price over two trading days [6]. Group 2: Company Background - F5 is described as a global multi-cloud application security and delivery company, enabling customers to deploy, secure, and operate applications both on-premises and via public cloud [3]. - The company's flagship product, BIG-IP, was notably affected by the security breach, which is also its highest revenue-generating product [6]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased F5 securities during the Class Period to seek appointment as lead plaintiff in the lawsuit [7]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and acts on behalf of all class members [7]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [8]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [8].

Core Viewpoint - Klarna Group plc is facing a class action lawsuit related to its September 10, 2025 IPO, alleging violations of the Securities Act of 1933 due to misleading offering documents and understated risks associated with its loss reserves [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Nayak v. Klarna Group plc and was filed in the Eastern District of New York [1]. - Investors who purchased Klarna securities during the IPO have until February 20, 2026, to seek appointment as lead plaintiff [1]. - The lawsuit claims that Klarna's IPO documents were materially false and omitted critical information regarding the company's financial risks [3]. Group 2: Financial Performance and Allegations - Klarna's IPO involved the issuance of approximately 34 million shares at an offering price of $40.00 per share [2]. - Following the IPO, Klarna reported a net loss of $95 million and increased provisions for loan losses to $235 million, exceeding analyst estimates of $215.8 million [4]. - Provisions for loan losses represented 0.72% of gross merchandise volume, an increase from 0.44% the previous year [4]. - By the time the class action lawsuit commenced, Klarna's stock price had fallen to as low as $31.31 per share, significantly below the IPO price [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows investors to seek lead plaintiff status if they have the greatest financial interest in the case [5]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Halper Sadeh LLC is investigating Clearwater Analytics Holdings, Inc. and Janus Henderson Group plc for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their respective sales to private equity firms at specified cash prices per share [1][2]. Group 1: Clearwater Analytics Holdings, Inc. - Clearwater Analytics is being sold to Permira and Warburg Pincus for $24.55 per share in cash [1]. - The investigation may seek increased consideration for shareholders and additional disclosures regarding the transaction [3]. Group 2: Janus Henderson Group plc - Janus Henderson is being sold to Trian Fund Management and General Catalyst for $49.00 per share in cash [2]. - Similar to Clearwater, the investigation may pursue increased consideration and additional disclosures for Janus shareholders [3]. Group 3: Legal Representation and Support - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4]. - The firm represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4].